Jove
Visualize
Contact Us

Related Experiment Videos

Chemotherapy-induced secondary malignancies.

Teri Vega-Stromberg1

  • 1St. Joseph Regional Medical Center, Nursing Office, Milwaukee, WI 53210, USA. tstrombe@covhealth.org

Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society
|November 19, 2003
PubMed
Summary

Chemotherapy protocols can increase the risk of secondary cancers, particularly hematologic malignancies like leukemia and lymphoma, in cancer survivors. Lifelong surveillance is crucial for these high-risk individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perceived readiness for hospital discharge in adult medical-surgical patients.

Clinical nurse specialist CNS·2007
Same author

Advances in colon cancer chemotheapy: nursing implications.

Home healthcare nurse·2005
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Cancer Research
  • Carcinogenesis

Background:

  • Chemotherapy protocols have evolved, impacting secondary cancer risks in vulnerable patient groups.
  • Certain chemotherapy agents, including alkylating agents, topoisomerase inhibitors, and anthracyclines, are strongly associated with initiating carcinogenesis.
  • Normal cells in bone marrow, hair follicles, and the gastrointestinal tract are particularly susceptible to chemotherapy-induced damage and subsequent carcinogenesis.

Purpose of the Study:

  • To analyze the influence of changing chemotherapy protocols on the incidence and risk of secondary malignancies.
  • To identify specific chemotherapy agents and cellular targets associated with increased carcinogenesis risk.
  • To highlight the heightened risk of secondary hematologic cancers in cancer survivors.

Main Methods:

Related Experiment Videos

  • Review of existing literature on chemotherapy protocols and secondary malignancy rates.
  • Analysis of data linking specific drug classes (alkylating agents, topoisomerase inhibitors, anthracyclines) to carcinogenesis.
  • Identification of sensitive cell types (bone marrow, hair follicles, GI epithelium) prone to chemotherapy-induced cancer.

Main Results:

  • Alkylating agents, topoisomerase inhibitors, and anthracyclines represent the highest risk for initiating secondary cancers.
  • Bone marrow, hair follicles, and gastrointestinal epithelial cells are particularly vulnerable to chemotherapy and carcinogenesis.
  • Secondary hematologic cancers, such as leukemia and lymphoma, are the most significant risks for adult and childhood cancer survivors.

Conclusions:

  • Changes in chemotherapy regimens necessitate careful consideration of secondary malignancy risks.
  • Survivors treated with high-risk agents require ongoing monitoring for secondary cancers, especially hematologic types.
  • Lifelong surveillance is recommended for adult and childhood cancer survivors due to the persistent risk of secondary malignancies.